Since its inception in 1998, Seattle Genetics has been making great strides in the biotechnology field through its cancer treatment research and ADC technology. Early this year, it unveiled a strategic plan to propel the company into more growth in a bid to meet its objectives. As so, Seattle Genetics through its CEO, Clay Siegall, revealed a plan to expand its drug pipeline with additional drugs as well as hire more employees.
Seattle Genetics has been undertaking numerous tests of ADCETRIS, the company’s only commercialized drug. According to Clay Siegall, the drug has been involved in over 70 trials against different types of lymphomas. Further, he revealed that the company was subjecting ADCETRIS to a Phase 3 clinical trial that utilizes ADCETRIS as the first treatment for formerly untreated or newly detected Hodgkin lymphoma.
Clay also told the Puget Sound Business Journal about Seattle Genetics’ plans to add more employees. By the end of the year, Seattle Genetics intends to add about 20 employees in its Switzerland office and 100 in its US office. The recruits are expected to join its team of over 800 employees.
Since co-founding the Seattle Genetics in 1998, Clay Siegall has appeared severally in the headlines due to his effort in steering the company to greater heights. As Seattle Genetics’ chairperson of the Board and CEO, Siegall has played an instrumental role in spearheading the company into making strategic agreements with other players in the drug industry. Some of these companies involved in such deals include Pfizer, GlaxoSmithKline, Genentech and AbbVie. By leveraging the technology from Seattle Genetics, over 20 ADCs are currently under clinical development across collaborator and internal programs.
Clay holds an undergraduate degree in zoology from the University of Maryland and a Ph.D. in Genetics from The George Washington University. Apart from being the president and CEO of Seattle Genetics, he holds key executive roles. Clay is a member of the board of directors of Alder Biopharmaceuticals Inc., Mirna Therapeuticals, Inc. and Ultragenyx Pharmaceuticals. Further, he holds several accolades such as the Alumnus of the Year for Computer, Math and Natural Sciences from the University of Maryland and the Pacific Northwest Ernst & Young Entrepreneur of the Year award.